Structure Therapeutics (NASDAQ:GPCR) Issues Quarterly Earnings Results

Structure Therapeutics (NASDAQ:GPCR) released its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10), FiscalAI reports.

Structure Therapeutics Stock Up 1.0%

NASDAQ GPCR traded up $0.52 during trading hours on Friday, reaching $53.14. The company’s stock had a trading volume of 329,459 shares, compared to its average volume of 558,888. Structure Therapeutics has a 1 year low of $15.86 and a 1 year high of $94.90. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -53.14 and a beta of -1.43. The firm’s 50-day moving average price is $47.63 and its 200-day moving average price is $54.19.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after purchasing an additional 1,432,797 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Structure Therapeutics by 14.4% during the fourth quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock valued at $354,006,000 after purchasing an additional 641,322 shares in the last quarter. Morgan Stanley grew its position in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after purchasing an additional 1,510,093 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Structure Therapeutics by 477.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after purchasing an additional 1,381,745 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Structure Therapeutics by 7.2% in the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock worth $32,939,000 after purchasing an additional 106,389 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

GPCR has been the subject of several analyst reports. Citizens Jmp reduced their price objective on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a research note on Friday. HC Wainwright lowered their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a report on Friday. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $110.91.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.